# US 8,278,326 B2 · Inhibitors of protein phosphatase-1 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,326 B2
- Document ID: US8278326B2
- Status: Granted
- Kind: B2
- Application number: 12/424,243
- Filed: 2009-04-15
- Published: 2009-10-22
- Granted: 2012-10-02
- Earliest claimed: 2008-04-16
- Assignees: Howard University
- Inventors: Sergei Nekhai; Dmytro Borysovich Kovalskyy
- Web page: https://patentgrep.com/patent/US8278326B2

## CPC

- C07D 219/04: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- A61P 31/18: for HIV
- C07D 221/16: containing carbocyclic rings other than six-membered
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Inhibitors of Protein Phosphatase-1 have been shown to slow replication of HIV-1. Inhibitors of PP 1 and their use for treatment or prevention of HIV-1 infections are disclosed.

## Claims

### Claim 1

A compound of formula (I) comprising:
wherein n is 1 or 2;
Ar is phenyl or thienyl, and is optionally substituted;
each R1 is independently R6, C(O)R6, C(O)—OR6, or C(O)N(R 6)2;
R2 is H or optionally substituted C1-C6 alkyl, or a group of formula —C(O)NH—R1;
R3 is independently at each occurrence selected from halo, NO2, CN, R, OR, NR2;
S(O)qR, COOR, and CONR2, where each R is independently H, C1-C4 alkyl, or C1-C4 haloalkyl;
m is 0-4;
R4 is R6, halo, =0, COOR6, CO N(R6)2, S(O)qR6, N(R6)2, or OR6;
p is 0-2;
each q is independently 0-2;
Z is 0 or NR5;
R5 is R6 or C(O)R6; and
R6 is independently at each occurrence selected from H, C1-C6 alkyl, C5-C6 aryl, and (C5-C6-aryl)-C1-C6 alkyl, where each alkyl and aryl is optionally substituted;
provided that n is 2 when Z is 0 and Ar represents para-halophenyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, comprising a pharmaceutically acceptable salt of a compound of formula I.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Z is O.

### Claim 4 (depends on 1)

The compound of claim 1, wherein n is 1.

### Claim 5 (depends on 1)

The compound of claim 1, wherein n is 2.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R2 is H or C1-C4 alkyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Ar is optionally substituted phenyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Ar is optionally substituted 2-thienyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein Ar is optionally substituted 3-thienyl.

### Claim 10

A pharmaceutical composition comprising a compound of formula (I) admixed with at least one pharmaceutically acceptable excipient or diluent.

### Claim 11

A method for treating a subject infected with or at risk of infection with HIV-1, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (I).

### Claim 12

A method to inhibit replication of HIV-1 virus, comprising contacting the HIV-1 virus or a cell containing the HIV-1 virus with a compound of formula (I).

### Claim 13

A compound selected from the group consisting of
and pharmaceutically acceptable salts of these compounds.

### Claim 14

A method for treating a subject infected with or at risk of infection with HIV-1, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of Compound A
and pharmaceutically acceptable salts of these compounds.

### Claim 15

A method to inhibit replication of HIV-1 virus, comprising contacting the HIV-1
virus or a cell containing the HIV-1 virus with a compound selected from the group consisting of Compound A
and pharmaceutically acceptable salts of these compounds.
